Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Duloxetine’s Dual Names: Lilly Wants Yentreve As Incontinence Brand

  • News

Executive Summary

Lilly is asking FDA to accept Yentreve as the trade name for duloxetine for the treatment of stress urinary incontinence

You may also be interested in...



Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer

Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory

Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer

Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory

Lilly Cymbalta Approval Timeline In Doubt After Delay In Second NDA

Lilly's plans to launch Cymbalta at the start of 2004 appear to hinge on the company's ability to convince FDA that the drug interaction issues delaying approval of duloxetine for incontinence should not hold up availability of the drug for depression

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS042682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By